{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:54:46Z","timestamp":1793145286582,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF-24-132"],"award-info":[{"award-number":["BCRF-24-132"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","award":["015669-00001"],"award-info":[{"award-number":["015669-00001"]}],"id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zymeworks"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA014089"],"award-info":[{"award-number":["P30 CA014089"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The use of antibody-drug conjugates (ADCs) specific to human epidermal growth factor receptor 2 (HER2), such as ado-trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (Enhertu, T-DXd), and trastuzumab duocarmazine (SYD985), to treat breast cancer patients has been associated with a variety of toxicities including corneal epithelial keratitis. The anatomic basis for ocular toxicities has not been established. Using immunohistochemistry, HER2 expression was identified in the human corneal, limbal and conjunctival epithelium of fetal and adult human eyes. We also identified HER2 expression in tissues from the\n                    <jats:italic>Macaca fascicularis<\/jats:italic>\n                    (monkey) to confirm a similar distribution of HER2 expression as found in humans and to support the use of this species as a toxicology model in preclinical testing of anti-HER2 ADCs. As in the human, expression of HER2 in monkey was limited to normal epithelium, as illustrated for the eye, kidney, and uterus. Incubation of normal human corneal epithelial cell lines with trastuzumab or T-DXd demonstrated the capacity for receptor-mediated endocytosis of HER2-targeted therapies by epithelia in the eye. Our findings of HER2 expression in normal human corneal epithelium suggest that the ocular adverse events associated with HER2-targeted ADCs may be driven, at least in part, by an on-target effect.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-51353-w","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:15:26Z","timestamp":1778170526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates"],"prefix":"10.1038","volume":"16","author":[{"given":"Simon","family":"Davenport","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Hamblett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Hausman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivonne","family":"Villalobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardeep P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cobrinik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S. B.","family":"Hoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Yuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sibug-Saber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried E.","family":"Konecny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Heur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis J.","family":"Slamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Press","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"51353_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon, D. J. et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235, 177\u2013182. https:\/\/doi.org\/10.1126\/science.3798106 (1987).","journal-title":"Science"},{"key":"51353_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon, D. J. et al. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707\u2013712. https:\/\/doi.org\/10.1126\/science.2470152 (1989).","journal-title":"Science"},{"key":"51353_CR3","first-page":"4960","volume":"53","author":"MF Press","year":"1993","unstructured":"Press, M. F. et al. Her-2\/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 53, 4960\u20134970 (1993).","journal-title":"Cancer Res."},{"key":"51353_CR4","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1200\/JCO.1997.15.8.2894","volume":"15","author":"MF Press","year":"1997","unstructured":"Press, M. F. et al. HER-2\/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J. Clin. Oncol. 15, 2894\u20132904. https:\/\/doi.org\/10.1200\/JCO.1997.15.8.2894 (1997).","journal-title":"J. Clin. Oncol."},{"key":"51353_CR5","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783\u2013792. https:\/\/doi.org\/10.1056\/NEJM200103153441101 (2001).","journal-title":"N. Engl. J. Med."},{"key":"51353_CR6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3816\/CBC.2005.n.026","volume":"6","author":"RD Mass","year":"2005","unstructured":"Mass, R. D. et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin. Breast Cancer 6, 240\u2013246. https:\/\/doi.org\/10.3816\/CBC.2005.n.026 (2005).","journal-title":"Clin. Breast Cancer"},{"key":"51353_CR7","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659\u20131672. https:\/\/doi.org\/10.1056\/NEJMoa052306 (2005).","journal-title":"N. Engl. J. Med."},{"key":"51353_CR8","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673\u20131684. https:\/\/doi.org\/10.1056\/NEJMoa052122 (2005).","journal-title":"N. Engl. J. Med."},{"key":"51353_CR9","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon, D. et al. Adjuvant Trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365, 1273\u20131283. https:\/\/doi.org\/10.1056\/NEJMoa0910383 (2011).","journal-title":"N. Engl. J. Med."},{"key":"51353_CR10","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1200\/JCO.19.01455","volume":"38","author":"L Fehrenbacher","year":"2020","unstructured":"Fehrenbacher, L. et al. NSABP B-47\/NRG Oncology Phase III randomized trial comparing adjuvant chemotherapy with or without Trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1\u2009+\u2009or 2. J. Clin. Oncol. 38, 444\u2013453. https:\/\/doi.org\/10.1200\/JCO.19.01455 (2020).","journal-title":"J. Clin. Oncol."},{"key":"51353_CR11","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cortes","year":"2022","unstructured":"Cortes, J. et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for breast cancer. N. Engl. J. Med. 386, 1143\u20131154. https:\/\/doi.org\/10.1056\/NEJMoa2115022 (2022).","journal-title":"N. Engl. J. Med."},{"key":"51353_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S. et al. Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. 387, 9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690 (2022).","journal-title":"N. Engl. J. Med."},{"key":"51353_CR13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10549-019-05179-y","volume":"175","author":"E Deklerck","year":"2019","unstructured":"Deklerck, E., Denys, H. & Kreps, E. O. Corneal features in Trastuzumab Emtansine treatment: Not a rare occurrence. Breast Cancer Res. Treat. 175, 525\u2013530. https:\/\/doi.org\/10.1007\/s10549-019-05179-y (2019).","journal-title":"Breast Cancer Res. Treat."},{"key":"51353_CR14","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","volume":"20","author":"U Banerji","year":"2019","unstructured":"Banerji, U. et al. Trastuzumab Duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: A Phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 20, 1124\u20131135. https:\/\/doi.org\/10.1016\/S1470-2045(19)30328-6 (2019).","journal-title":"Lancet Oncol."},{"key":"51353_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58266-8","volume":"16","author":"LC Tsao","year":"2025","unstructured":"Tsao, L. C. et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of Trastuzumab Deruxtecan (T-DXd). Nat. Commun. 16, 3167. https:\/\/doi.org\/10.1038\/s41467-025-58266-8 (2025).","journal-title":"Nat. Commun."},{"key":"51353_CR16","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani, Y., Hagihara, K., Oitate, M., Naito, H. & Agatsuma, T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 107, 1039\u20131046. https:\/\/doi.org\/10.1111\/cas.12966 (2016).","journal-title":"Cancer Sci."},{"key":"51353_CR17","first-page":"953","volume":"5","author":"MF Press","year":"1990","unstructured":"Press, M. F., Cordon-Cardo, C. & Slamon, D. J. Expression of the HER-2\/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5, 953\u2013962 (1990).","journal-title":"Oncogene"},{"key":"51353_CR18","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1200\/JCO.2009.27.5644","volume":"29","author":"MF Press","year":"2011","unstructured":"Press, M. F. et al. Alteration of topoisomerase II-alpha gene in human breast cancer: Association with responsiveness to anthracycline-based chemotherapy. J. Clin. Oncol. 29, 859\u2013867. https:\/\/doi.org\/10.1200\/JCO.2009.27.5644 (2011).","journal-title":"J. Clin. Oncol."},{"key":"51353_CR19","first-page":"2771","volume":"54","author":"MF Press","year":"1994","unstructured":"Press, M. F., Hung, G., Godolphin, W. & Slamon, D. J. Sensitivity of HER-2\/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 54, 2771\u20132777 (1994).","journal-title":"Cancer Res."},{"key":"51353_CR20","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1089\/hyb.1999.18.487","volume":"18","author":"JM Park","year":"1999","unstructured":"Park, J. M., Yang, X., Park, J. J., Press, O. W. & Press, M. F. Assessment of novel anti-p185HER-2 monoclonal antibodies for internalization-dependent therapies. Hybridoma 18, 487\u2013495. https:\/\/doi.org\/10.1089\/hyb.1999.18.487 (1999).","journal-title":"Hybridoma"},{"key":"51353_CR21","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1200\/JCO.2016.66.6693","volume":"34","author":"MF Press","year":"2016","unstructured":"Press, M. F. et al. HER2 gene amplification testing by fluorescent in situ hybridization (FISH): Comparison of the ASCO-College of American Pathologists guidelines with FISH scores used for enrollment in Breast Cancer International Research Group clinical trials. J. Clin. Oncol. 34, 3518\u20133528. https:\/\/doi.org\/10.1200\/JCO.2016.66.6693 (2016).","journal-title":"J. Clin. Oncol."},{"key":"51353_CR22","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.5858\/arpa.2016-0009-OA","volume":"140","author":"MF Press","year":"2016","unstructured":"Press, M. F. et al. Assessing the new American Society of Clinical Oncology\/College of American Pathologists guidelines for HER2 testing by fluorescence in situ hybridization: Experience of an academic consultation practice. Arch. Pathol. Lab. Med. 140, 1250\u20131258. https:\/\/doi.org\/10.5858\/arpa.2016-0009-OA (2016).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"51353_CR23","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1001\/jamaoncol.2018.6012","volume":"5","author":"MF Press","year":"2019","unstructured":"Press, M. F. et al. Assessment of ERBB2\/HER2 status in HER2-equivocal breast cancers by FISH and 2013\/2014 ASCO-CAP guidelines. JAMA Oncol. 5, 366\u2013375. https:\/\/doi.org\/10.1001\/jamaoncol.2018.6012 (2019).","journal-title":"JAMA Oncol."},{"key":"51353_CR24","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","volume":"31","author":"JS Eaton","year":"2015","unstructured":"Eaton, J. S., Miller, P. E., Mannis, M. J. & Murphy, C. J. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J. Ocul. Pharmacol. Ther. 31, 589\u2013604. https:\/\/doi.org\/10.1089\/jop.2015.0064 (2015).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"51353_CR25","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1111\/jcpt.13777","volume":"47","author":"Z Guo","year":"2022","unstructured":"Guo, Z. et al. Safety of trastuzumab deruxtecan: A meta-analysis and pharmacovigilance study. J. Clin. Pharm. Ther. 47, 1837\u20131844. https:\/\/doi.org\/10.1111\/jcpt.13777 (2022).","journal-title":"J. Clin. Pharm. Ther."},{"key":"51353_CR26","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.1002\/cncr.27622","volume":"118","author":"M Beeram","year":"2012","unstructured":"Beeram, M. et al. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer 118, 5733\u20135740. https:\/\/doi.org\/10.1002\/cncr.27622 (2012).","journal-title":"Cancer"},{"key":"51353_CR27","doi-asserted-by":"publisher","unstructured":"Zhang, J. et al. Phase I Trial of a Novel Anti-HER2 Antibody-Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer. Clin. Cancer Res. OF1-OF10 https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0456 (2022).","DOI":"10.1158\/1078-0432.CCR-22-0456"},{"key":"51353_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00522-5","volume":"9","author":"J Zhang","year":"2023","unstructured":"Zhang, J. et al. Phase I study of A166, an antibody\u2012drug conjugate in advanced HER2-expressing solid tumours. NPJ Breast Cancer 9, 28. https:\/\/doi.org\/10.1038\/s41523-023-00522-5 (2023).","journal-title":"NPJ Breast Cancer"},{"key":"51353_CR29","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s10120-021-01168-7","volume":"24","author":"Y Xu","year":"2021","unstructured":"Xu, Y. et al. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer 24, 913\u2013925. https:\/\/doi.org\/10.1007\/s10120-021-01168-7 (2021).","journal-title":"Gastric Cancer"},{"key":"51353_CR30","doi-asserted-by":"publisher","unstructured":"Burris, H. A. 3rd. et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol. 29, 398\u2013405. https:\/\/doi.org\/10.1200\/JCO.2010.29.5865 (2011).","DOI":"10.1200\/JCO.2010.29.5865"},{"key":"51353_CR31","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1158\/1535-7163.MCT-23-0101","volume":"22","author":"F Meric-Bernstam","year":"2023","unstructured":"Meric-Bernstam, F. et al. Safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-expressing solid tumors: A phase 1 dose-escalation study. Mol. Cancer Ther. 22, 1191\u20131203. https:\/\/doi.org\/10.1158\/1535-7163.MCT-23-0101 (2023).","journal-title":"Mol. Cancer Ther."},{"key":"51353_CR32","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N. Engl. J. Med. 382, 610\u2013621. https:\/\/doi.org\/10.1056\/NEJMoa1914510 (2020).","journal-title":"N. Engl. J. Med."},{"key":"51353_CR33","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1158\/1535-7163.MCT-20-0237","volume":"19","author":"EI Graziani","year":"2020","unstructured":"Graziani, E. I. et al. PF-06804103, a site-specific Anti-HER2 antibody-drug conjugate for the treatment of HER2-expressing breast, gastric, and lung cancers. Mol. Cancer Ther. 19, 2068\u20132078. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0237 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"51353_CR34","doi-asserted-by":"publisher","first-page":"7861","DOI":"10.1158\/1078-0432.CCR-08-1056","volume":"14","author":"MF Press","year":"2008","unstructured":"Press, M. F. et al. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin. Cancer Res. 14, 7861\u20137870. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1056 (2008).","journal-title":"Clin. Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51353-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51353-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51353-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:34:12Z","timestamp":1783899252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51353-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["51353"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-51353-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MFP discloses the following conflicts of interest: Employment: none; Leadership; none; Stock or other ownership: none; Consulting or advisory roles in AstraZeneca, Inc.; Cepheid, Inc.; Eli Lily & Company; Merck & Co.; Zymeworks, Inc.; Novartis Pharmaceuticals; ANGLE; Private Equity: TORL Biotherapeutics, LLC; Travel, accommodations or expenses: none. The funding agencies played no role in the decision to publish or the content of the manuscript. These determinations were made exclusively by the co-authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21731"}}